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Abstract
Background: Advanced glycation end products (AGEs) are associated with aging, diabetes mellitus (DM), and other
chronic diseases. Recently, the accumulation of AGEs can be evaluated by skin autofluorescence (SAF). However, the
relationship between SAF levels and exercise capacity in patients with cardiovascular disease (CVD) remains unclear.
This study aimed to investigate the association between the tissue accumulation of AGEs and clinical characteristics,
including exercise capacity, in patients with CVD.
Methods: We enrolled 319 consecutive CVD patients aged ≥40 years who underwent early phase II cardiac
rehabilitation (CR) at our university hospital between November 2015 and September 2017. Patient background,
clinical data, and the accumulation of AGEs assessed by SAF were recorded at the beginning of CR. Characteristics
were compared between two patient groups divided according to the median SAF level (High SAF and Low SAF).
Results: The High SAF group was significantly older and exhibited a higher prevalence of DM than the Low SAF
group. The sex ratio did not differ between the two groups. AGE levels showed significant negative correlations
with peak oxygen uptake and ventilator efficiency (both P < 0.0001). Exercise capacity was significantly lower in the
high SAF group than in the low SAF group, regardless of the presence or absence of DM (P < 0.05). A multivariate
logistic regression analysis showed that SAF level was an independent factor associated with reduced exercise
capacity (odds ratio 2.10; 95% confidence interval 1.13–4.05; P = 0.02).
Conclusion: High levels of tissue accumulated AGEs, as assessed by SAF, were significantly and independently
associated with reduced exercise capacity. These data suggest that measuring the tissue accumulation of AGEs may
be useful in patients who have undergone CR, irrespective of whether they have DM.
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Background
Exercise intolerance is recognized to be an important pre-
dictor of adverse outcomes in patients with cardiovascular
disease (CVD) [1–3]. Previous studies demonstrated higher
mortality rates in patients with heart failure (HF) with re-
duced exercise capacity (EC), especially in those with peak
oxygen uptake (peak VO2) ≤14mL/kg/min [4–7].
Advanced glycation end products (AGEs) are harmful
compounds formed when proteins, lipids, and nucleic
acids combine with glucose [8]. AGEs accumulate in the
body as a result of aging, food intake, and smoking. The
reactions that result in AGE accumulation are acceler-
ated under hyperglycemic conditions such as those
caused by diabetes mellitus (DM), and in inflammatory
conditions, and oxidative stress [9, 10]. AGEs have been
shown to directly crosslink proteins, including vascular
and muscle collagen, which alters the protein structure
and results in dysfunction [8, 11]. Previous studies of the
relationship between AGEs and physical function re-
ported that populations with high concentrations of the
AGE carboxymethyllysine are more likely to exhibit de-
creased grip strength and slower walking speed [12, 13].
Skin autofluorescence (SAF) has recently been devel-
oped as an accurate and noninvasive method to measure
AGE accumulation in the skin. SAF has received atten-
tion as its results can provide a useful predictor of all-
cause mortality and cardiovascular mortality in patients
who are high-risk [14–16].
Evidence that supports that the accumulation of AGEs
may be associated with reduced EC exists but whether
SAF levels are associated with reduced EC in patients
with CVD remains unclear. Thus, the aim of this study
was to investigate the association between SAF levels
and clinical characteristics in patients with CVD and to
evaluate the relationship between SAF levels and EC.
Methods
Study population
This retrospective cross-sectional study included 371
consecutive patients who underwent cardiopulmonary
exercise testing (CPX) at the beginning of phase II car-
diac rehabilitation (CR) at our university hospital be-
tween November 2015 and September 2017. Of these,
18 patients were excluded for being aged < 40 years, 34
were excluded because of a lack of SAF data. The final
study population consisted of 319 patients (Fig. 1). Writ-
ten informed consent was provided by all the patients
prior to participation. The study protocol was approved
by the ethical committee of our institution, and the
study was conducted in accordance with the principles
of the Helsinki Declaration.
Skin autofluorescence
SAF levels were measured with an AGE Reader (Diag-
nOptics Technologies B.V., Groningen, Netherlands)
[17]. This noninvasively evaluates the accumulation of
AGEs in the skin by measuring the level of fluorescence
with light excitation [18]. SAF levels were calculated as
the ratio of the average light intensity in the 420–600
nm wavelength range and the average excitation light in-
tensity in the 300–420 nm range. A previous study has
shown that AGEs bind and accumulate to collagen and
elastin in the epithelium and dermis [19]. A study of
healthy and diabetic subjects confirmed that SAF levels
Fig. 1 Flowchart of patient enrollment. Consecutive patients who underwent cardiopulmonary exercise testing (CPX) at the beginning of phase II
cardiac rehabilitation (CR) were enrolled, totaling 371. The final analysis included 319 patients. CPX, cardiopulmonary exercise test; CR, cardiac
rehabilitation; SAF, skin autofluorescence
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assessed by the AGE Reader correlated well with skin bi-
opsy assessments of the accumulation of AGEs such as
pentosidine and carboxymethyllysine [20]. Thus, SAF
levels provide an indication of the accumulation of AGEs
in the epithelium and dermis of the skin. In the present
study, SAF was measured from the inside of the forearm
while the patient was seated.
Data collection
Age, sex, smoking history, comorbidities, and medical
history were obtained from the patients’ medical records.
Blood samples were collected in the early morning after
overnight fasting. A diagnosis of DM was defined by
hemoglobin A1c ≥ 6.5% or by receiving treatment for
DM. Chronic kidney disease (CKD) was defined as an
estimated glomerular filtration rate (eGFR) < 60mL/
min/1.73 m2, calculated by the renal disease equation
with the Japanese coefficient, using baseline serum cre-
atinine and modification to diet [21].
Measurements
Body composition, grip strength, SAF level, and EC were
assessed at the beginning of CR. Anthropometric param-
eters, including the percentage of body fat, lean body
weight, and muscle mass, were measured by bioelectrical
impedance analysis (TANITA, MC-780A, Tokyo, Japan),
as described previously [22, 23]. Grip strength was tested
in both hands with the patient in a standing position; the
higher of the two grip strength values was used in the ana-
lysis. EC was assessed by CPX on a cycle ergometer
(Strength Ergo 8, Mitsubishi Electric Corp., Tokyo, Japan)
with an expiratory gas analysis machine (AE-310S, Minato
Medical Science Co., Ltd., Osaka, Japan). A ramp protocol
was used with a workload increase of 10W/min to measure
the anaerobic threshold and peak VO2. Heart rate was re-
corded continuously using a standard 12-lead electrocar-
diogram, and blood pressure was registered every minute
during the exercise testing. Peak VO2 was defined as the
highest VO2 value recorded during CPX. The anaerobic
threshold point was determined by the V-slope method, as
previously described [24]. Patients with a peak VO2 ≤ 14
mL/kg/min were categorized as having reduced EC; the
other patients were classified as having non-reduced EC.
Statistical analysis
Continuous variables are presented as mean ± standard
deviation. Comparisons between groups were evaluated
using Welch’s t test for continuous variables and the chi-
squared test for categorical variables. Logistic regression
models were used to examine relationships between re-
duced EC and other factors. We selected covariates with
significant differences determined as such by the compari-
son between the reduced EC and nonreduced EC groups
to input into the multivariate analysis. Differences were
considered statistically significant at P < 0.05. JMP version
12.0 (SAS Institute, Cary, NC, USA) was used to perform
the statistical analyses.
Results
Baseline characteristics and SAF data
In 319 subjects enrolled in the present study, mean age
was 66 ± 12 years old, and 256 patients were male (80.3%).
Figure 2 shows the distribution of SAF levels. The values
of mean and median SAF levels were 2.9 ± 0.6 a.u and 2.8
a.u (interquartile range: 2.5, 3.2 a.u), respectively.
Comparison between the high SAF and low SAF groups
The patients were divided into two groups based on the
median value of SAF. The High and Low SAF groups
comprised 159 and 160 participants, respectively. Table 1
compares the clinical characteristics between the two
groups. There was no significant difference in sex ratio.
Compared to the Low SAF group, the High SAF group
exhibited a significantly higher mean age, higher mean
body fat percentage, and higher prevalence of DM, CKD,
and a history of coronary artery bypass grafting. Cardiac
function defined as systolic and diastolic function was
similar between the two groups. Hemoglobin and albu-
min levels were significantly lower in the High SAF
group than in the Low SAF group, whereas HbA1c was
significantly higher. The anaerobic threshold and peak
VO2 of the High SAF group were significantly lower
than those of the Low SAF group (both P < 0.01).
Comparison between the diabetes and non-diabetes
groups
The patients were divided into two groups by DM status
and then classified as high or low SAF according to the me-
dian SAF level for the group (3.0 a.u. for the DM group and
2.7 a.u. for the non-DM group). Comparisons of the clinical
characteristics between the high and low SAF subgroups
tended to show the same trends in the DM and non-DM
groups (Supplemental Tables 1 and 2). In the DM group,
peak VO2 was significantly lower in the high SAF subgroup
than in the low SAF subgroup (14.5 ± 3.1 vs. 16.1 ± 3.9mL/
kg/min, respectively; P < 0.05). Similarly, in the non-DM
group, peakVO2 was significantly lower in the high SAF
subgroup compared to the low SAF subgroup (16.4 ± 3.5
vs. 17.5 ± 3.8mL/kg/min; P < 0.05) (Fig. 3).
Association between SAF levels and reduced EC
Reduced EC is considered to be clinically important [4–7].
Therefore, we performed a logistic regression analysis to
investigate the factors that were independently associated
with reduced EC, defined as peak VO2 ≤ 14mL/kg/min
(Supplemental Table 3 shows the comparisons of the clin-
ical characteristics between the reduced and non-reduced
EC groups). After adjusting for age, sex, BMI, DM, Atrial
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fibrillation, body fat percentage, E/e’, albumin, eGFR,
HDL-cholesterol, BNP, aspirin and SAF, SAF level was
found to be a significant independent factor associated
with reduced EC (odds ratio 2.10, 95% confidence interval
1.13–4.05; P = 0.02) (Table 2).
Discussion
The results of this study showed that EC was significantly
lower in patients with higher SAF levels regardless of their
DM status and that SAF levels were independently associ-
ated with reduced EC, even while cardiac systolic and dia-
stolic function were similar between both groups. To the
best of our knowledge, this is the first study to demon-
strate an association between SAF levels and reduced EC
among patients with CVD who underwent CR.
Several studies reported an association between plasma
AGEs and lower physical function in community-dwelling
elderly people [12, 13]. In addition, a study of a Japanese
population reported that SAF levels were significantly
higher in the study group with lower muscle mass (de-
fined by the Asian Working Group for Sarcopenia’s skel-
etal muscle mass index criteria) and were a significant
independent factor associated with low skeletal muscle
index values [17]. The results of the present study further
confirm the relationship between SAF levels and reduced
EC. This is an important finding because impaired EC is
known to be a powerful predictor of poor prognosis [1–3].
A previous study of patients with HF with systolic dys-
function reported that SAF level were significantly higher
and EC was significantly lower in patients with DM than
in those without DM [25]. In addition, the patients with
SAF levels above the mean value demonstrated lower EC
[25]. Our findings are consistent with those of the previ-
ous report, and we additionally found that patients with
higher SAF levels demonstrated significantly lower EC,
even in the patients without DM.
It has been reported that patients with DM showed re-
duced muscle function and EC [26–28]. Although the
determinants of impaired physical function in patients
with DM are poorly understood, several mechanisms
have been proposed [29]. Previous studies demonstrated
an inverse correlation between EC measured by peak
VO2 and insulin resistance, and that increased SAF
levels were positively associated with insulin resistance
in patients with DM [30–32]. It has also been reported
that serum AGE levels were positively correlated with
insulin resistance even in non-DM patients [33]. Fur-
thermore, previous studies reported that diabetes and
hyperglycemia are associated with mitochondrial dys-
function and increased levels of mitochondrial reactive
oxygen species in the vasculature, resulting in endothe-
lial nitric oxide synthase inhibition [34, 35]. In addition
to these direct effects, AGEs can bind with AGE recep-
tors, which can result in endothelial dysfunction and the
enhanced production of reactive oxygen species [36].
Animal experiments suggested that endothelial nitric
oxide could be a factor in EC regulation [34–37]. Cross-
linking of myocardial collagen with AGEs may contrib-
ute to increased myocardial stiffness and diastolic
dysfunction [11, 36]. In addition, left ventricular diastolic
dysfunction due to DM is associated with decreased left
ventricular compliance, resulting in a restricted ability to
increase cardiac output during exercise, thereby limiting
EC [38, 39]. Previous studies have reported that diastolic
dysfunction assessed by E/e’ is a strong predictor of exer-
cise intolerance, and this association was independent of
DM [40, 41]. Consistent with these studies, our investiga-
tion demonstrated that E/e’ was one of the significant fac-
tors influencing reduced EC. In the present study, age was
also associated with reduced EC. It has been suggested
that the effects of aging on exercise intolerance are due in
part to decreased activity and changes in body compos-
ition [42]. Moreover, the accumulation of AGEs has also
Fig. 2 Distribution of SAF levels. The values of mean and median SAF levels were 2.9 ± 0.6 a.u and 2.8 a.u (interquartile range: 2.5, 3.2 a.u),
respectively. Shapiro–Wilk test of normality: P < 0.05. SAF, skin autofluorescence; DM, diabetes mellitus
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Table 1 Patient characteristics
High SAF(n = 159) Low SAF(n = 160) P value
Age 67.9 ± 10.4 60.6 ± 11.8 < 0.01
Male (%) 127 (79.9) 129 (80.6) 0.87
BMI 23.7 ± 3.5 23.3 ± 3.3 0.38
Diabetes mellitus (%) 69 (43.4) 38 (23.8) < 0.01
Hypertension (%) 107 (67.3) 102 (63.8) 0.51
Dyslipidemia (%) 86 (54.1) 86 (53.8) 0.95
Chronic kidney disease (%) 46 (28.9) 28 (17.6) 0.02
Current smoking (%) 22 (13.8) 22 (13.8) 1
COPD (%) 14 (8.8) 5 (3.1) 0.03
Cancer (%) 0 (0) 3 (1.9) 0.21
History of CVD
MI (%) 19 (12.0) 16 (10.0) 0.58
PCI (%) 34 (21.4) 22 (13.8) 0.07
CABG (%) 9 (5.7) 6 (3.8) 0.41
Valvular surgery (%) 10 (6.3) 6 (3.8) 0.29
CHF (%) 32 (20.1) 27 (16.9) 0.45
CVD at the beginning of CR
Acute myocardial infarction (%) 20 (12.6) 19 (11.9) 0.85
Effort angina pectoris (%) 28 (17.6)) 20 (12.5) 0.20
PCI (%) 28 (17.6) 25 (15.6) 0.63
CABG (%) 45 (28.3) 24 (15.0) < 0.01
Valvular disease (%) 58 (36.5) 59 (36.9) 0.94
Valvular surgery (%) 47 (29.8) 50 (31.3) 0.77
Aortic disease (%) 10 (6.3) 13 (8.1) 0.53
Peripheral artery disease (%) 8 (5.0) 3 (1.9) 0.12
Atrial fibrillation (%) 24 (15.1) 26 (16.3) 0.78
Anthropometric data
Body fat percentage (%) 23.4 ± 7.7 21.4 ± 8.5 0.03
Lean body weight (kg) 48.6 ± 8.4 50.1 ± 8.7 0.13
Trunk muscle mass (kg) 24.8 ± 3.9 25.7 ± 4.2 0.06
Upper limb muscle mass (kg) 4.6 ± 1.0 4.8 ± 1.0 0.15
Lower limb muscle mass (kg) 16.6 ± 4.0 17.1 ± 3.5 0.32
Grip strength (kg) 29.9 ± 8.2 32.3 ± 8.4 0.04
Echocardiography
LVEF (%) 56 ± 14 57 ± 15 0.74
E/A 1.3 ± 0.9 1.4 ± 0.9 0.42
E/e’ 14.1 ± 0.7 13.0 ± 0.7 0.28
Laboratory data
Hemoglobin (g/dL) 13.3 ± 1.9 13.9 ± 1.7 < 0.01
Albumin (g/dL) 3.9 ± 0.4 4.0 ± 0.5 0.03
Creatinine (mg/dL) 1.11 ± 1.4 0.8 ± 0.3 < 0.01
eGFR (mL/min/1.73 m2) 70.1 ± 25.7 77.2 ± 19.4 < 0.01
TG (mg/dL) 114 ± 63 130 ± 87 0.07
HDL cholesterol (mg/dL) 49 ± 15 50 ± 16 0.68
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Table 1 Patient characteristics (Continued)
High SAF(n = 159) Low SAF(n = 160) P value
LDL cholesterol (mg/dL) 100 ± 28 100 ± 30 0.88
HbA1c (%) 6.1 ± 0.8 5.8 ± 0.6 < 0.01
BNP (pg/nL) 200.6 ± 516.0 160 ± 287 0.40
Skin autofluorescence (a.u) 3.3 ± 0.4 2.4 ± 0.3 < 0.01
Medication
Aspirin (%) 130 (82.3) 12 (78.1) 0.35
ACE-I/ARB (%) 66 (41.8) 62 (38.8) 0.58
Statin (%) 106 (67.1) 87 (54.4) 0.02
β blocker (%) 116 (73.4) 116 (72.5) 0.85
Ca antagonist (%) 29 (18.4) 21 (13.1) 0.20
Loop diuretics (%) 110 (69.6) 108 (67.5) 0.68
Oral hypoglycemic agent (%) 35 (22.2) 13 (8.1) < 0.01
Insulin (%) 14 (8.9) 0 (0) < 0.01
Anaerobic threshold (AT)
Workload (W) 43 ± 14 49 ± 15 < 0.01
AT (mL/kg/min) 10.7 ± 2.2 11.8 ± 2.5 < 0.01
Peak exercise
HR (/min) 111 ± 19 116 ± 20 0.03
SBP (mmHg) 178 ± 30 173 ± 31 0.16
DBP (mmHg) 86 ± 17 87 ± 17 0.41
RER 1.12 ± 0.11 1.11 ± 0.10 0.18
Workload (W) 77 ± 20 86 ± 21 < 0.01
Peak VO2 (mL/kg/min) 15.6 ± 3.5 17.2 ± 3.8 < 0.01
VE/VCO2 32.4 ± 7.5 29.5 ± 6.5 < 0.01
High SAF; defined as SAF levels > 2.8
Data are presented as the mean value ± SD. BMI body mass index, COPD chronic obstructive pulmonary disease, CVD cardiovascular disease, MI myocardial
infarction, PCI percutaneous coronary intervention, CABG coronary artery bypass graft, CHF congestive heart failure, CR cardiac rehabilitation, LV left ventricular, EF
ejection fraction, E early diastolic filling velocity, A late diastolic filling velocity, e’ early diastolic tissue velocity, eGFR estimate glomerular filtration rate, TG
triglyceride, HDL high-density lipoprotein cholesterol, LDL low-density lipoprotein cholesterol, HbA1c hemoglobin A1c, BNP B-type natriuretic peptide, HR heart
rate, SBP systolic blood pressure, DBP diastolic blood pressure, RER respiratory exchange ratio, peak VO2 peak oxygen uptake
Fig. 3 Comparison of peak oxygen uptake (VO2) levels between the High (> 2.8 a.u.) and low (≤ 2.8 a.u.) SAF groups. Regardless of the presence
or absence of DM, peak VO2 levels were significantly lower in the high SAF group than in the low SAF group. SAF, skin autofluorescence; DM,
diabetes mellitus
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been observed to be associated with aging, lifestyle habits
such as specific food intake, and smoking, in addition to the
presence of chronic inflammatory conditions such as meta-
bolic syndrome, arteriosclerosis, and renal disease [9, 10, 43].
The deterioration of EC with AGE accumulation may, there-
fore, be the result of AGEs causing the functional decline of
several organ systems that regulate EC, regardless of DM
status. A recent meta-analysis demonstrated that SAF levels
were a predictor of mortality in high-risk patients [15]. This
could potentially be explained by the association between
high SAF levels and reduced EC observed in the present
study. As for interventions, a recent study reported that ala-
gebrium, proposed as an AGE-breaker, did not ameliorate
EC and cardiac function, but also failed to lower SAF levels
in patients with HF [44]. Thus, further studies are needed to
elucidate the mechanisms by which AGEs affect EC.
Body fat percentage also tended to have an effect on re-
duced EC in the present study. Although interactions be-
tween AGEs and adipocytes have not been fully clarified
[45], the accumulation of body fat may relate to deterior-
ation in insulin sensitivity, increased intracellular lipids in
skeletal muscle, and the decreased metabolic ability of
mitochondria, ultimately resulting in decreased oxygen in-
take during exercise [46–49].
This study exhibits several limitations. First, this was a
single-center and retrospective cross-sectional study with a
small sample size, so we could not establish a causal rela-
tionship between SAF level and reduced EC. Second, we
enrolled patients with CVD who underwent CR. Third, the
method of SAF assessment did not measure the total accu-
mulation of all AGEs in the body. Fourth, SAF represents
not only the fluorescence values resulting from skin AGEs,
but also from other fluorophores such as keratin, therefore
assessment of SAF may not be an accurate measurement of
the skin’s AGE content [50]. Fifth, previous studies suggest
that the reliability of AGE analysis in skin may depend on
skin color, as this affects the skin’s tendency to absorb exci-
tation light [51]. Sixth, SAF is strongly influenced by the
use of skin creams, which leads to elevated SAF values and
decreased skin reflectance [52]. Seventh, SAF is a surrogate
marker of tissue accumulation of AGEs. Whether skin
AGEs reflect the accumulation of AGEs in cardiac tissue is
an important question, and further investigations are
needed to answer it. Finally, the diagnosis of DM may have
been underestimated because some patients did not
undergo an oral glucose tolerance test.
Conclusion
In conclusion, this study demonstrated that high levels
of tissue accumulated AGEs, as assessed by SAF, were
significantly and independently associated with reduced
EC. These data suggest that the measurement of the tis-
sue accumulation of AGEs may be useful for patients
undergoing CR, including those without DM. Further
studies should be carried out to determine whether ele-
vated SAF levels are a specific predicter of decline in EC
in patients undergoing CR and to corroborate these
findings in other patients with CVD.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12872-020-01484-3.
Additional file 1: Table S1. Comparison of clinical characteristics
between High SAF (> 3.0 a. u.) and Low SAF (≤ 3.0 a.u.) groups in DM
(diabetes mellitus) patients.
Table 2 Logistic regression analysis of reduced EC
Variables Univariate Multivariate
Odds ratio 95% CI P value Odds ratio 95% CI P value
Age 1.05 1.03–1.08 < 0.01 1.04 1.00–1.09 0.04
Female 1.82 1.01–3.22 < 0.05 0.97 0.31–2.96 0.96
BMI 1.08 1.01–1.17 < 0.05 0.98 0.83–1.15 0.76
Diabetes mellitus 2.64 1.61–4.38 < 0.01 1.56 0.74–3.26 0.24
Atrial fibrillation 3.99 2.15–7.52 < 0.01 1.48 0.55–3.90 0.43
Albumin 0.45 0.26–0.77 < 0.01 1.22 0.56–2.72 0.62
eGFR 0.97 0.96–0.99 < 0.01 0.99 0.97–1.01 0.18
BNP 1.00 1.00–1.002 < 0.01 1.00 0.99–1.00 0.73
E/e’ 1.06 1.02–1.10 < 0.01 1.05 1.00–1.10 0.04
Body fat percentage 1.09 1.05–1.13 < 0.01 1.07 0.99–1.16 0.054
HDL cholesterol 0.98 0.96–0.99 < 0.05 0.98 0.96–1.01 0.14
Aspirin 0.46 0.26–0.83 < 0.01 0.57 0.20–1.63 0.29
SAF 2.63 1.72–4.13 < 0.01 2.10 1.13–4.05 0.02
EC exercise capacity, CI confidence interval, BMI body mass index, eGFR estimate glomerular filtration rate, BNP B-type natriuretic peptide, E early diastolic filling
velocity, e’ early diastolic tissue velocity, HDL high density lipoproteins, SAF skin autofluorescence
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Additional file 2: Table S2. Comparison of clinical characteristics
between (> 2.7 a.u.) and Low SAF (≤ 2.7 a.u.) groups in non DM (diabetes
mellitus) patients.
Additional file 3: Table S3. Comparison of clinical characteristics
between reduced EC and non-reduced EC groups.
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